Kathy Littrell | Head of Investor Relations |
Bruce Cozadd | CEO |
Dan Swisher | President |
Renee Gala | CFO |
Rob Iannone | Executive Vice President, R&D |
Mike Miller | Executive Vice President, U.S. Commercial |
Phil Jockelson | Sweep and Neuroscience Therapeutic Head |
Ann Borgman | Hematology and Oncology Therapeutic Head |
Jed Black | Senior Vice President, Sleep and Neuroscience |
Sean Mendes | Senior Vice President, Strategy and Finance |
Brandon Folkes | Cantor Fitzgerald |
Gary Nachman | BMO Capital Markets |
David Amsellem | Piper Sandler |
Greg Gilbert | SunTrust |
Jacob Hughes | Wells Fargo Securities |
Akash Tewari | Wolfe Research |
Jason Gerberry | Bank of America |
Ami Fadia | SVB Leerink |
Jessica Fye | JPMorgan |
Ken Cacciatore | Cowen and Company |
Randall Stanicky | RBC Capital Markets |
Annabel Samimy | Stifel |
Ronny Gal | Bernstein |
Balaji Prasad | Barclays |
David Risinger | Morgan Stanley |
Esther Rajavelu | Oppenheimer |
Umer Raffat | Evercore ISI |
Welcome to the Jazz Pharmaceuticals plc First Quarter 2020 Earnings Conference Call.
Following an introduction from the company, we will open the call for questions. I will now turn the call over to Kathy Littrell, Head of Investor Relations at Jazz Pharmaceuticals.
Thank you, Valerie, and thanks to those of you joining our investor call. Today, we reported our first quarter 2020 financial results and updated our financial guidance for 2020.